ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 35 filers reported holding ASCENDIS PHARMA A/S in Q2 2017. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,809,000 | -93.4% | 27,208 | -92.5% | 0.08% | -97.9% |
| Q1 2019 | $42,468,000 | -0.3% | 360,819 | -46.9% | 3.92% | -8.1% |
| Q4 2018 | $42,586,000 | -44.7% | 679,746 | -37.5% | 4.26% | -38.6% |
| Q3 2018 | $77,043,000 | -20.9% | 1,087,257 | -25.7% | 6.94% | -25.1% |
| Q2 2018 | $97,390,000 | -18.3% | 1,464,067 | -19.7% | 9.27% | -22.4% |
| Q1 2018 | $119,196,000 | +41.2% | 1,822,575 | -13.5% | 11.96% | +25.7% |
| Q4 2017 | $84,430,000 | +10.5% | 2,107,600 | 0.0% | 9.51% | -6.6% |
| Q3 2017 | $76,401,000 | +85.6% | 2,107,600 | +42.2% | 10.18% | +39.4% |
| Q2 2017 | $41,157,000 | +43.3% | 1,482,600 | +44.5% | 7.31% | +0.6% |
| Q1 2017 | $28,720,000 | +45.4% | 1,025,700 | +5.1% | 7.26% | +15.5% |
| Q4 2016 | $19,748,000 | +348.2% | 975,700 | +345.1% | 6.29% | +365.0% |
| Q3 2016 | $4,406,000 | – | 219,200 | – | 1.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |